KONINKLIJKE PHILIPS NV (PHG): what the price assumes

In the published model solve dated 2026-Q2, anchored at $26.57, KONINKLIJKE PHILIPS NV (PHG) is priced for +8.9% growth. boothcheck publishes no house fair value, target price, or buy/sell rating; individual model outputs and user-controlled scenarios are analytical inputs, not Boothcheck targets. Narrative composed 2026-06-28.

Generated: 2026-08-10 · Exported: 2026-08-12 · Source: https://boothcheck.com/report/PHG

Headline

What The Price Assumes (Inversion)

The assumption today's price embeds, recovered by inverting the valuation.

The operating-margin figure is value-band context at year 12: derived from the framework's value band, a separate calculation — not part of the priced-in solve.

Solve inputs: computed at a 8.1% cost of capital with 4% terminal growth over a 5-year stage; each 1pp of cost of capital moves the implied operating-profit growth ~7.2pp.

Reconcile: at the x-ray's 9.3% required return this reads ~16.7%/yr; the models below use their own rates.

How unusual the bet is: within-range (limited comparison data)

Valuation X-Ray

The price is justified by relative-multiple; asset-based/earnings-power/growth-DCF land below the price.

How the valuation models price the stock relative to the market price. Price/FV above 1.0 means the market pays more than that lens defends (expensive); at or below 1.0 the lens can defend the price.

Families that justify the price: Relative Families that call it expensive: Asset, Earnings, Growth

The models below discount at their own flat-beta convention rates (cost of equity 9.3%, WACC 7.6%); the inversion above states its own rate.

Per-Model Detail (n=13)

Solvency

Bullet Takeaways

• Philips is a global health-technology company spanning diagnostic imaging, patient monitoring, and personal health products, now run as a focused medical business after years of reshaping its portfolio.
• The dominant overhang is the Respironics recall, which cost the company a roughly 1 billion euro cash payment for settlements in the latest year, with a US Department of Justice investigation still open and excluded from guidance.
• The recovery is real but partial: reported profitability remains thin on a trailing basis, while the company guides to an adjusted operating margin in the 12.5% to 13.0% range for 2026 against a fresh tariff headwind of about 250 million to 300 million euros.

Bull Case

Start with what has gone wrong, because the bull case is fundamentally a recovery story, and recovery only makes sense against the depth of the hole. Philips spent years mired in the Respironics recall, the withdrawal of sleep-and-respiratory devices that triggered massive provisions, litigation, and a regulatory cloud that crushed the stock and the reported earnings. The trailing financials still show the damage: a thin reported operating margin and net income depressed by recall costs. That is the bear's starting point, and it is real. But the pivot is that the worst of the cash outflow is now visible and quantified. Philips made a roughly 1 billion euro cash payment for recall-related settlements in the latest year and still swung to a net profit, from a loss the year before. The largest known liability is being worked through rather than expanding into the unknown.

Underneath the overhang sits a genuine medical-technology franchise. Philips holds strong positions in diagnostic imaging, image-guided therapy, and patient monitoring, businesses with installed bases that generate recurring service and consumables revenue, plus a personal-health arm with globally recognized consumer brands. The recovery in the operating numbers shows the underlying business was never the problem. The adjusted operating margin rose to about 12.3% from 11.5%, supported by roughly 0.8 billion euros of productivity savings, and the company guides that margin toward 12.5% to 13.0% for 2026. Order growth has been accelerating even as the recall noise persists, which says demand for the core products is intact.

The valuation reflects the overhang, not the franchise, and that is the opportunity. The relative-multiple lens, valuing Philips against the medical-technology sector on earnings, lands above the current price, because the sector commands a healthy multiple and Philips trades at a discount to it. The market is pricing the recall risk and the depressed trailing margins, not the normalized earnings power of a recovering med-tech company guiding to a low-teens adjusted margin and rising free cash flow. For an investor willing to underwrite the litigation tail, the bull case is a quality health-technology business bought while the market still treats it as a damaged one.

Bear Case

The most fragile assumption in the price is that the Respironics chapter is closing, and it is not fully closed. Philips has settled the bulk of the personal-injury and economic-loss litigation and made large cash payments, but a US Department of Justice investigation remains open, and the company explicitly excludes it from its outlook. An excluded liability is an uncapped one for valuation purposes: the bull case assumes the recall is a known, declining cost, but a DOJ resolution could bring further penalties, a consent decree, or operating restrictions whose size and timing are not visible. A recovery thesis that depends on a legal tail staying quiet is exposing the investor to an outcome no one can size from the financials.

The reported earnings power is the second fragility, and it is starker than the adjusted numbers suggest. On a trailing GAAP basis, the operating margin is barely positive and interest coverage is weak, because the recall provisions, restructuring, and other charges sit between the adjusted figures the company emphasizes and the actual earnings. The gap between a roughly 12% adjusted operating margin and a near-zero reported one is not noise; it is the running cost of the cleanup, and it has persisted for years. Net debt of about 6 billion euros against this depressed reported operating income is heavy leverage when measured against the earnings the company actually books, even if it looks more manageable against the adjusted figure. The price asks the investor to believe the reported number converges quickly toward the adjusted one, and that convergence has been slower than management has repeatedly guided.

The macro and competitive pressures compound the recovery risk. Philips faces a fresh tariff headwind of about 250 to 300 million euros for 2026, a direct hit to a margin recovery that is still in progress, and its Greater China business, an important market for imaging equipment, is expected to stay flat amid weak hospital capital spending. In its core imaging and monitoring markets it competes against larger, financially stronger rivals with deeper R&D budgets. The bear case is that the valuation already credits a clean recovery, while the company still carries an open regulatory investigation, a wide gap between adjusted and reported earnings, real leverage against thin GAAP profit, and external headwinds pressing on the very margin expansion the price assumes.

Valuation

Philips trades on a recovery bet: that reported profitability climbs back toward the adjusted margins management reports, and that the Respironics liabilities finish declining rather than reopening. The inversion frames the price as embedding modest operating-income growth, around 9%, off a depressed base, which is a sensible shape for a turnaround but rests entirely on the depressed base being temporary. The single most important caveat in the whole valuation is the gap between the roughly 12% adjusted operating margin the company guides to and the near-zero reported margin in the trailing data; the price is paying for that gap to close.

The methods split sharply around that gap. The relative-multiple lens, valuing Philips at a medical-technology sector earnings multiple, lands above the price, treating the company as a normalized med-tech business. But the asset-based, earnings-power, and growth methods all read expensive, because they capitalize the actual reported earnings, which are still suppressed by recall and restructuring costs. The earnings-power method, in particular, lands far below the price, since normalizing the trailing operating income produces almost nothing to capitalize. That divergence is the entire valuation question in one picture: if you believe the adjusted margins are the true earnings power, the relative lens says the stock is cheap; if you believe the reported numbers, every other method says it is expensive. The truth depends on how fast and how completely the recovery and the litigation resolution play out.

Solvency is where the recovery bet meets its constraint. Net debt of about 6 billion euros sits against trailing reported operating income that is thin, so leverage looks heavy on the reported numbers even if it is comfortable on the adjusted ones, and interest coverage on the GAAP figure is weak. The company is generating free cash flow again, guiding to roughly 1.3 to 1.5 billion euros for 2026, which is the genuine sign the business is healing, and it is not burning cash. What the buyer is underwriting is convergence and closure: reported earnings rising toward adjusted levels as the recall costs roll off, and the open DOJ matter resolving without a large surprise. The downside is bounded by the value of the franchise; the upside requires the cleanup to actually finish.

Catalysts

Philips is guiding to comparable sales growth of 3% to 4.5% for 2026, an adjusted operating margin of 12.5% to 13.0%, and free cash flow of roughly 1.3 to 1.5 billion euros. The recovery showed in the 2025 results: net income swung from a loss of about 698 million euros in 2024 to a profit of about 897 million euros in 2025, with the adjusted operating margin rising to about 12.3% from 11.5% on roughly 0.8 billion euros of productivity savings, even after a roughly 1 billion euro cash payment for Respironics settlements. Q1 2026 showed accelerating order growth despite an EPS miss. The next prints are the read on whether reported margins keep converging toward the adjusted guidance.

The catalysts that will move the thesis are the litigation tail and the macro headwinds. The open US Department of Justice investigation, excluded from guidance, is the binary overhang: a resolution removing it would lift the recall cloud, while an adverse outcome would extend it. On the operating side, the company flagged a tariff headwind of about 250 to 300 million euros for 2026 and expects Greater China to stay flat, both pressing on the margin recovery. Analyst sentiment is cautiously positive, with a recent Buy rating and a $30.30 price target against a price near $27. The developments to watch are any DOJ resolution, the pace at which reported margins close the gap to the adjusted figures, and order trends in the core imaging business, since those determine whether the recovery thesis converts to durable earnings.

Peer Cohorts (Per Segment, With Filing Citations)

Core business (reported)

• GEHC (GE HEALTHCARE TECHNOLOGIES INC.)
• FY2025 10-K: …The increase as a percent of sales was driven by unfavorable mix within our service offerings, and cost inflation, including the impact of incremental tariffs, partially offset by an increase in pricing of our service offerings. Included in our total cost of revenues as part of our product investment was $490 million…
• FY2025 10-K: …we face a wide variety of competitors, including a broad range of manufacturers, third-party distributors, and service providers. In the industries we serve, we believe our primary global competitors include Siemens Healthineers, Philips Healthcare, United Imaging, Mindray, and Canon, among others. In our PDx…
• BDX (BECTON DICKINSON & CO)
• FY2025 10-K: …acquisition date, as well as the impact from amortization of intangibles acquired in the transaction which occurred on September 3, 2024. 45 Table of Contents The favorable impact on gross margin from specified items in 2024 compared with 2023 primarily reflected a favorable comparison to specified items recorded in…
• FY2025 10-K: …of Contents Notes to Consolidated Financial Statements - (Continued) Becton, Dickinson and Company The following tables include the significant expenses by segment that are regularly provided to the CODM and a reconciliation of segment operating income to Income from Continuing Operations before Income Taxes. Fiscal…
• THC (TENET HEALTHCARE CORP)
• FY2025 10-K: …of need in any jurisdiction where they are required, or if any jurisdiction will eliminate or alter its certificate of need requirements in a manner that will increase competition and, thereby, affect our competitive position. In those states that do not have certificate of need requirements or that do not require…
• FY2025 10-K: …healthcare consumers are able to access performance data on quality measures and patient satisfaction, as well as pricing information for services, to compare competing providers. In addition, the No Surprises Act requires providers to send to health plans of insured patients and to uninsured patients good faith…
• IQV (IQVIA HOLDINGS INC.)
• FY2025 10-K: …and other technological advances in a timely, cost-effective manner or to keep pace with rapid technological change could adversely affect our competitive position and our results of operations. Our future growth and success will depend on our ability to successfully compete with other companies that provide similar…
• FY2025 10-K: …entrants and start-ups that are looking to bring new technologies and business models to healthcare information services and technology services. The markets for Research & Development Solutions offerings are highly competitive, and we compete against traditional clinical research organizations ("CROs"), the in-house…
• REGN (REGENERON PHARMACEUTICALS, INC.)
• FY2025 10-K: …developed in collaboration with our collaborators) and the substantial competition they face, see also Part I, Item 1A. "Risk Factors - Risks Related to Commercialization of Our Marketed Products, Product Candidates, and New Indications for Our Marketed Products - The commercial success of our products and product…
• FY2025 10-K: …providers, and business partners and customers; and the demand for our marketed products. Such disruptions in our operations could materially adversely impact our business, prospects, operating results, and financial condition. To the extent a public health outbreak, epidemic, or pandemic adversely affects our…
• MMM (3M COMPANY)
• FY2025 10-K: …of the Company's Health Care business, including the risk that the expected benefits will not be realized; the risk that the costs or dis-synergies will exceed the anticipated amounts; potential impacts on the Company's relationships with its customers, suppliers, employees, regulators and other counterparties; the…
• FY2025 10-K: …within the Notes to Consolidated Financial Statements. 13 Table of Contents Risks Related to Our Products and Customer Preferences * The Company's results are affected by competitive conditions and customer preferences. Demand for the Company's products, which impacts revenue and profit margins, is affected by, among…
• VTRS (Viatris Inc)
• FY2025 10-K: …We take very seriously our continued and comprehensive oversight of our entire manufacturing network. Patient safety remains our primary and unwavering focus. We will work closely with our customers to mitigate any possible supply disruptions and meet the needs of the patients we serve. For additional information,…
• FY2025 10-K: …to the increase in cost of sales. Adjusted gross margins were approximately 56% for the year ended December 31, 2025, compared to 58% for the year ended December 31, 2024. 64 Table of Contents A reconciliation between cost of sales, as reported under U.S. GAAP, and adjusted cost of sales and adjusted gross margin for…
• SYK (STRYKER CORP)
• FY2025 10-K: …medical products and services. Such downward pricing pressures from any or all of these payers may result in an adverse effect on our business, results of operations, financial condition and cash flows. We have also reduced prices for certain products due to increased competition and if we further reduce prices, we…
• FY2025 10-K: …products restricts competitors from duplicating these unique designs and features. We seek to obtain patent protection on our products whenever appropriate for protecting our competitive advantage. On December 31, 2025 we owned approximately 5,600 United States patents and approximately 9,000 patents in other…

Methodology Note

• Priced-in inversion: the valuation is inverted on the current price to recover the operating-income growth, duration, and steady-state margin the price embeds (ROE for financials, FFO growth for REITs).
• Valuation x-ray: the valuation models, grouped into four families (asset, earnings, relative, growth). Each model is expressed as a price/FV ratio (distance from price), not a point fair-value estimate. The spread across families is the disagreement.
• Solvency: net cash/debt, net-debt-to-NOPAT, interest coverage, and share-count CAGR from EDGAR financials (net debt / FFO and fixed-charge coverage for REITs; regulatory-capital framing for financials).
• Peer cohorts: per-segment comparables with deep-linkable SEC filing citations.

Fundamentals sourced from SEC EDGAR filings. Current price from Databento. The priced-in inversion and valuation x-ray are computed by the boothcheck engine; narrative composed by AI from the structured data.